The content on this site is intended for healthcare professionals only
Dr Rudin presents at ASCO 2016, early findings from a first-in-human clinical trial which showed that antibody drug conjugate (ADC) rovalpituzumab tesirine (Rova-T) demonstrated promising efficacy against recurrent small cell lung cancer (SCLC).
Read the news story for more.
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Updates on lung cancer from WCLC and ESMO 2023
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert round up July 28th to August 3rd, 2023
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
